Antibiotique sélectif Geneticin™ (sulfate G418), poudre
Antibiotique sélectif Geneticin™ (sulfate G418), poudre
Antibiotique sélectif Geneticin™ (sulfate G418), poudre
Gibco™

Antibiotique sélectif Geneticin™ (sulfate G418), poudre

L’antibiotique sélectif Geneticin™ (G418 Sulfate) est produit par la bactérie Micromonospora rhodorangea et agit en liant le ribosome, inhibant ainsiAfficher plus
Have Questions?
Modifier l'affichagebuttonViewtableView
RéférenceQuantité
118110231 g
118110315 g
1181109825 g
Référence 11811023
Prix (EUR)
213,00
Each
Quantité:
1 g
Prix (EUR)
213,00
Each
L’antibiotique sélectif Geneticin™ (G418 Sulfate) est produit par la bactérie Micromonospora rhodorangea et agit en liant le ribosome, inhibant ainsi la synthèse protéique dans les cellules procaryotes et eucaryotes. La résistance à l’antibiotique sélectif Geneticin™ (sulfate G418) est conférée par les gènes de résistance E. coli APH(3’) – I et APH(3’) – II. L’antibiotique sélectif Geneticin™ Gibco™ (sulfate G418) est utilisé comme antibiotique sélectif dans une plage de concentration de 100 à 200 µg / ml pour les bactéries, ou 200 à 500 µg / ml pour la plupart des cellules de mammifères. Ce produit est fourni sous forme de poudre et doit être transformé en solution mère dans 10 à 50 mg / ml d’eau. Nous proposons une grande variété d’antibiotiques pour la culture cellulaire pour votre commodité.

Utilisation du produit
Usage exclusivement réservé à la recherche : Non destiné au diagnostic ou à l’usage thérapeutique chez l’animal ou l’humain.

Système de qualité et fabrication conforme aux BPFa sur deux sites
Pour assurer la continuité de la chaîne d’approvisionnement, nous fabriquons l’antibiotique sélectif Geneticin™ Gibco™ (sulfate G418) sur deux sites distincts situés à Grand Island, dans l’État de New York et en Écosse, au Royaume-Uni. Les deux sites sont conformes aux BPFa, certifiés ISO 13485 et homologués par la FDA comme fabricants de dispositifs médicaux.

Usage exclusivement réservé à la recherche. Ne pas utiliser pour des procédures de diagnostic.

Spécifications
Type de celluleCellules eucaryotes, cellules pokaryotiques
Concentration10 à 50 μg/ml
À utiliser avec (application)Sélection eucaryote ⁄ génération de lignées cellulaires stables
Gamme de produitsGeneticin
Quantité1 g
Durée de conservation24 mois
Conditions d’expéditionTempérature ambiante
FormePoudre
Type de produitAntibiotique
StérilitéNon-sterile
Unit SizeEach
Contenu et stockage
Conditions de stockage : 15 à 30°C
Conditions d’expédition : température ambiante
Durée de conservation : 24 mois à compter de la date de fabrication

Foire aux questions (FAQ)

Which of your antibiotics (Geneticin, Zeocin, Hygromycin B, Blasticidin, and Puromycin) can be used together for stable selection in mammalian cells?

All of our antibiotics (Geneticin, Zeocin, Hygromycin B, Blasticidin, and Puromycin) can be used together for making multiple stable cell lines. However, kill curves will need to be performed for each combination of antibiotics since sensitivity to a given antibiotic tends to increase when combined with other antibiotics.

Can Neomycin be used in mammalian selection?  Can Neomycin be used instead of Kanamycin in bacterial selection?

No, Neomycin is toxic to mammalian cells. It also causes irreversible damage to kidneys and other organs. Geneticin (aka G418 Sulfate) is a less toxic and very effective alternative for selection in mammalian cells.  Neomycin can be used in bacterial selection, but Kanamycin is the preferred drug to use because of Neomycin's toxicity.

What are the recommended concentrations of antibiotics to use for selection in prokaryotes and eukaryotes?

For best results, optimal concentrations for selection should be determined empirically in each unique experiment through dose response curves. However, to get a general idea of concentrations that have worked for individual cell types, please click on the following url: http://www.thermofisher.com/us/en/home/life-science/cell-culture/transfection/selection.html or type in “Selection Antibiotics” into our main search on www.thermofisher.com.

In contrast to Geneticin (G418)-induced cell death, cells treated with Zeocin do not always detach and float when they die. Is this typical?

It is true that a percentage of non-resistant mammalian cells do not round-up from the plate upon Zeocin selection as would be seen with G418 or Hygromycin selection. However, one should see some very characteristic morphological changes occurring in those cells that are not resistant. These cells that stick to the culture dish typically display a vast increase in size. This could be best described as being similar to the effects of cytomegalovirus infecting permissive cells. The shape of these cells may also change; taking on an "alien" shape. On close examination of the non-resistant cells, the researcher should observe a distinct breakdown of both the nuclear and plasma membranes. Even though the "cells" are still attached to the plate, they should have the appearance of many holes in these membranes. Also, before the breakdown of the membranes, one can observe open areas in the cytoplasm of the cells that appear to be large, empty vesicles. Although not confirmed, this may be explained by a breakdown of the endoplasmic reticulum and Golgi apparatus, or other scaffolding proteins. Eventually, these "cells" will completely breakdown so that only "strings" of protein are left.

In contrast, Zeocin resistant cells should continue to divide at a regular interval to form distinct clumps of cells, or colonies. There should not be a distinct change in morphology, which can be compared to cells not under selection with Zeocin. It is these colonies of actively dividing cells that contain the resistance gene and are expressing it actively.

If there is concern about the dead cells sticking to the plate, one may do the following to eliminate them: Treat the plate for a couple of minutes with trypsin/versene. Both the healthy resistant cells and the dead cells will dislodge from the plate. The cells can then be replated (without Zeocin selection) and the healthy cells will attach again while the dead ones will not. After a couple of hours when the healthy cells have attached to the substrate again, Zeocin can be added back to the medium.

What is the mode of action on the following antibiotics: Blasticidin, Geneticin (G418), Hygromycin, and Zeocin?

Blasticidin: Nucleoside Inhibits protein synthesis in prokaryotic and eukaryotic cells by interfering with peptidyl transfer reaction of protein synthesis, causing early termination of translation.

Geneticin (G418): Aminoglycoside Blocks protein synthesis in mammalian cells by interfering with ribosomal function.

Hygromycin: Aminocyclitol Inhibits protein synthesis by disrupting translocation and promoting mistranslation.

Zeocin: Intercalates with DNA and cleaves it.

Citations et références (147)

Citations et références
Abstract
Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells.
Authors:Endo T; Ohta K; Haraguchi K; Onaya T;
Journal:J Biol Chem
PubMed ID:7738021
Thyrotropin receptor (TSH-R) has been thought to be thyroid-specific, but, by Northern blot analysis, we found that rat adipose tissue expressed TSH-R mRNAs in amounts approaching those in the thyroid. To investigate the function of TSH-R from adipose tissue, we screened a rat fat cell lambda gt11 cDNA library for ... More
The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain.
Authors:Celie Patrick H N; Van Stempvoort Gunny; Fribourg Caroline; Schurgers Leon J; Lenting Peter J; Mertens Koen;
Journal:J Biol Chem
PubMed ID:11925427
The light chain of activated factor IX comprises multiple interactions between both epidermal growth factor-like domains that contribute to enzymatic activity and binding of factor IXa to its cofactor factor VIIIa. To investigate the association between factor IXa-specific properties and surface-exposed structure elements, chimeras were constructed in which the interconnection ... More
DBC2, a candidate for a tumor suppressor gene involved in breast cancer.
Authors:Hamaguchi Masaaki; Meth Jennifer L; von Klitzing Christine; Wei Wen; Esposito Diane; Rodgers Linda; Walsh Tom; Welcsh Piri; King Mary-Claire; Wigler Michael H;
Journal:Proc Natl Acad Sci U S A
PubMed ID:12370419
A previously uncharacterized gene, DBC2 (deleted in breast cancer), was cloned from a homozygously deleted region at human chromosome 8p21. DBC2 contains a highly conserved RAS domain and two putative protein interacting domains. Our analyses indicate that DBC2 is the best candidate tumor suppressor gene from this region. It lies ... More
Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells.
Authors:Xie Jianwu; LeBaron Matthew J; Nevalainen Marja T; Rui Hallgeir;
Journal:J Biol Chem
PubMed ID:11821424
Genetic studies in mice have established a critical role for prolactin receptors and transcription factor Stat5 in mammary gland differentiation. However, the enzymatic coupling between prolactin receptors and Stat5 in this process has not been established. In addition to Jak2, several other tyrosine kinases reportedly also are associated with prolactin ... More
A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function.
Authors: Ruvolo Peter P; Clark Warren; Mumby Marc; Gao Fengqin; May W Stratford;
Journal:J Biol Chem
PubMed ID:11929874
'Recently it has been shown that the potent apoptotic agent ceramide activates a mitochondrial protein phosphatase 2A (PP2A) and promotes dephosphorylation of the anti-apoptotic molecule Bcl2 (Ruvolo, P. P., Deng, X., Ito, T., Carr, B. K., and May, W. S. (1999) J. Biol. Chem. 274, 20296-20300). In cells expressing Bcl2, ... More